Evidence map›Paper›PMID 34399829›Full record

ArticleParasites & vectors2021

Evaluation of two Plasmodium vivax sexual stage antigens as transmission-blocking vaccine candidates.

Yongzhe Zhang, Fei Liu, Yan Zhao, Fan Yang, Jie Bai, Xitong Jia, Wanlapa Roobsoong, Jetsumon Sattabongkot, Liwang Cui, Yaming Cao and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Parasites & vectors, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 3 countries.

Yongzhe Zhang *Department of Pathogen Biology, College of Basic Medical Sciences, China Medical University, Shenyang, 110122, Liaoning, China.
Fei Liu *Department of Immunology, College of Basic Medical Sciences, China Medical University, Shenyang, 110122, Liaoning, China.
Yan Zhao *Department of Immunology, College of Basic Medical Sciences, China Medical University, Shenyang, 110122, Liaoning, China.
Fan YangDepartment of Immunology, College of Basic Medical Sciences, China Medical University, Shenyang, 110122, Liaoning, China.
Jie BaiDepartment of Immunology, College of Basic Medical Sciences, China Medical University, Shenyang, 110122, Liaoning, China.
Xitong JiaDepartment of Pathogen Biology, College of Basic Medical Sciences, China Medical University, Shenyang, 110122, Liaoning, China.
Wanlapa RoobsoongMahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Jetsumon SattabongkotMahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Liwang CuiDepartment of Internal Medicine, Morsani College of Medicine, University of South Florida, 3720 Spectrum Boulevard, Suite 304, Tampa, FL, 33612-9415, USA.
Yaming CaoDepartment of Immunology, College of Basic Medical Sciences, China Medical University, Shenyang, 110122, Liaoning, China.
Enjie LuoDepartment of Pathogen Biology, College of Basic Medical Sciences, China Medical University, Shenyang, 110122, Liaoning, China. ejluo@cmu.edu.cn.
Meilian WangDepartment of Pathogen Biology, College of Basic Medical Sciences, China Medical University, Shenyang, 110122, Liaoning, China. wangmeilian_m@hotmail.com.
China Medical University · CNMahidol University · THUniversity of South Florida · US

Funding

Southeast Asia Malaria Research CenterU19AI089672 · NIAID · UNIVERSITY OF SOUTH FLORIDA · PI CUI, LIWANG · 2010 to 2023
$28.9M
NIAID NIH HHS U19 AI089672
6 · The paper itself

Abstract

backgroundPlasmodium vivax transmission-blocking vaccines (TBVs) are receiving increasing attention. Based on excellent transmission-blocking activities of the PbPH (PBANKA_0417200) and PbSOP26 (PBANKA_1457700) antigens in Plasmodium berghei, their orthologs in P. vivax, PVX_098655 (PvPH) and PVX_101120 (PvSOP26), were selected for the evaluation of their potential as TBVs.

methodsFragments of PvPH (amino acids 22-304) and PvSOP26 (amino acids 30-272) were expressed in the yeast expression system. The recombinant proteins were used to immunize mice to obtain antisera. The transmission-reducing activities of these antisera were evaluated using the direct membrane feeding assay (DMFA) using Anopheles dirus mosquitoes and P. vivax clinical isolates.

resultsThe recombinant proteins PvPH and PvSOP26 induced robust antibody responses in mice. The DMFA showed that the anti-PvSOP26 sera significantly reduced oocyst densities by 92.0 and 84.1% in two parasite isolates, respectively, whereas the anti-PvPH sera did not show evident transmission-reducing activity. The variation in the DMFA results was unlikely due to the genetic polymorphisms of the two genes since their respective sequences were identical in the clinical P. vivax isolates.

conclusionPvSOP26 could be a promising TBV candidate for P. vivax, which warrants further evaluation.

Indexed as

AnimalsAntibodies, ProtozoanAntigens, ProtozoanFemaleHumansImmunogenicity, VaccineMalaria VaccinesMalaria, VivaxMiceMice, Inbred BALB CPlasmodium vivaxProtozoan ProteinsRecombinant ProteinsVaccinationVaccines, SyntheticYeastsAntibodies, ProtozoanAntigens, ProtozoanMalaria VaccinesProtozoan ProteinsRecombinant ProteinsVaccines, SyntheticDirect membrane feeding assayPlasmodium vivaxTransmission-blocking vaccineYeast expression

Identifiers

PMID34399829
PMCPMC8366161
OpenAlexW3140805764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.